Inspira Technologies Oxy B.H.N. Ltd. reports developments in Additively Manufactured Electronics, quantum connectivity and its medical technology portfolio. Company updates focus on AME system orders and deployments, QTREX-branded cryogenic interconnect work for superconducting quantum systems, customer activity with research, defense and technology organizations, and leadership or strategic-direction announcements.
The company's medical technology context includes respiratory support and blood monitoring platforms, including INSPIRA ART, INSPIRA ART100 and the HYLA Blood Sensor, while recent communications emphasize a dedicated medical business unit alongside the AME and quantum connectivity strategy.
Inspira (NASDAQ: IINN, IINNW) priced a registered direct offering of 6,785,715 ordinary shares at $0.70 per share, expected to raise approximately $4.75 million gross, plus a concurrent private placement of unregistered warrants to purchase up to 6,785,715 shares.
The warrants have an exercise price of $0.70, become exercisable six months after issuance, and expire 5.5 years from issuance. Closing is expected on or about February 6, 2026. The company also agreed to amend certain existing warrants to a $0.70 exercise price.
Inspira Technologies (NASDAQ: IINN) validated its Next-Generation Standalone HYLA blood sensor, reporting 94.2% accuracy for continuous pCO₂ measurement concordant within a 7 mmHg threshold. The standalone configuration targets an immediate commercial pathway into the ~$48 billion heart-lung surgery market and plans a U.S. FDA submission in 2026. The strategy emphasizes disposable optical sensors and modular software for recurring revenue and broader OR/ICU integration.
Inspira Technologies (NASDAQ: IINN) announced its FDA-cleared INSPIRA ART100 completed full clinical evaluation and moved from pilot use to routine workflow at a top U.S. academic medical center.
Approximately 30 patients were treated across multiple indications and the hospital has begun a budgeted procurement process for multiple ART100 systems.
Inspira (NASDAQ: IINN) said two previously announced binding purchase orders — $22.5 million (July 2, 2025) and $27 million (August 19, 2025) — have advanced to the final budgetary validation and fund allocation stage within relevant governmental procurement processes.
The company reported that ~91% of the orders have cleared commercial and administrative review and are undergoing the concluding budgetary authorization step prior to fund release and execution. Inspira expects payment and revenue recognition during the 2026 fiscal cycle, subject to customary governmental approvals, and says internal execution preparations are complete.
Inspira (NASDAQ: IINN) outlined a strategic vision and a proposed transaction framework to expand into liquid biopsy diagnostics through a contemplated acquisition of an advanced liquid biopsy platform and a concurrent equity investment. The company says the structure is designed to preserve shareholder value, enable future dividend distributions from its core respiratory and life-support technologies, and allocate value via a CVR framework. Inspira highlights its HYLA blood sensor (clinical accuracy reported at 95%–99% across measured parameters), an established blood diagnostics laboratory, and prior FDA 510(k) clearance of the ART100 system as foundations to accelerate regulatory and commercial progress for the new platform.
Inspira (NASDAQ: IINN) entered a non-binding term sheet dated Jan 5, 2026 for a proposed all‑share acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment based on a $180 million pre-money valuation.
The company expects to sign Definitive Agreements within approximately four weeks, then seek shareholder approval and satisfy customary closing conditions. Inspira plans to allocate $12 million of the investment to existing respiratory and blood‑monitoring technology development. The acquired platform showed high concordance with tissue biopsies in clinical validation across dozens of samples and the company expects to pursue FDA 510(k) clearance; an existing reimbursement code is noted.
Inspira (NASDAQ: IINN) entered a non-binding term sheet on Jan 5, 2026 for an all-share acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment based on a $180 million pre-money valuation. The Company expects to sign Definitive Agreements within ~four weeks, subject to shareholder approval and customary closing conditions.
The plan allocates $12 million of proceeds to existing respiratory and blood-monitoring technology development, proposes contingent value rights to protect current shareholders, and aims for FDA 510(k) clearance for the platform previously validated across dozens of patient samples.
Inspira Technologies (NASDAQ:IINN) reaffirmed its previously announced $49.5 million in binding purchase orders and said payment activity and revenue recognition are structured to commence in the 2026 fiscal cycle. The company said the orders remain in full force based on representations from its distributor and that execution timing reflects regulatory sequencing, technical implementation requirements, and coordination of institutional funding.
Inspira highlighted active coordination with distribution partners, regulators, and funding organizations to finalize delivery schedules, reduce execution risk, and support a phased rollout across target markets, and expects to provide further updates as milestones are met.
Inspira Technologies (NASDAQ: IINN, IINNW) entered a definitive agreement for a registered direct offering of 1,565,217 ordinary shares at $1.15 per share, producing gross proceeds of approximately $1.8 million. The offering is expected to close on or about December 16, 2025 and will be sold pursuant to a prospectus supplement under a Form F-3 shelf declared effective on December 12, 2025.
Separately, Inspira signed a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., giving the company the right to sell up to $25 million of ordinary shares over 36 months at its discretion, with no minimum purchase requirements. Net proceeds are intended for working capital and general corporate purposes.
Inspira Technologies (NASDAQ: IINN) said the Japan Patent Office granted Patent No. 7777598 on Dec 9, 2025 for its Convertible Dual Lumen Cannula and method of use, giving exclusive commercial rights in Japan through 2041.
The patent complements an earlier U.S. patent granted in 2023, creating IP protection across two major healthcare markets. The device converts a single-lumen cannula intravascularly into a dual-lumen cannula after insertion, aiming to let physicians switch modes without additional incisions. Management said this supports potential standalone disposable commercialization and integration into the INSPIRA™ ART System.